Simvastatin downregulates the expression of hepcidin and erythropoietin in HepG2 cells

Hemodialysis International

Volumn 17, Issue 1, 2013, Pages 116-121

  Chang, Chia Chu ^a,b   Chiu, Ping Fang ^a,b   Chen, Hung Lin ^a   Chang, Tzu Lan ^a   Chang, Yu Jun ^a   Huang, Ching Hui ^a,b  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Erythropoietin; Erythropoietin receptor; Hepcidin; Simvastatin

Indexed keywords

COMPLEMENTARY DNA; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEPCIDIN; MESSENGER RNA; SIMVASTATIN;

ARTICLE; CELL CULTURE; CELL STRAIN HEPG2; CONTROLLED STUDY; DNA EXTRACTION; DOWN REGULATION; HOMEOSTASIS; HUMAN; HUMAN CELL; IRON METABOLISM; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIMICROBIAL CATIONIC PEPTIDES; CELL LINE; DOWN-REGULATION; ERYTHROPOIETIN; HEP G2 CELLS; HEPCIDINS; HUMANS; RNA, MESSENGER; SIMVASTATIN;

EID: 84872652158     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2012.00716.x     Document Type: Article

References (31)

1. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005; 352:1011-1023.
2. National Kidney Foundation. NKF K/DOQI clinical practice guidelines for anemia of chronic kidney disease. Am J Kidney Dis. 2001; 37:S182-S238.
3. Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant. 2001; 16:S25-S28.
4. Gunell G, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999; 33:63-72.
5. Krause A, Neitz S, Magert HJ, etal. LEAP-1, a novel highly disulfide bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000; 480:147-150.
6. Nemeth E, Tuttle MS, Powelson J, etal. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306:2090-2093.
7. Dallalio G, Law E, Means RT Jr. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood. 2006; 107:2702-2704.
8. Tsouchnikas I, Dounousi E, Papakonstantinou S, etal. Beneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemodialysis patients. Nephrology. 2009; 14:560-564.
9. Chiang CK, Yang SY, Peng YS, etal. Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: Role of anti-inflammation effects. Am J Nephrol. 2009; 29:392-397.
10. Arabul M, Gullulu M, Yilmaz Y, etal. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease. Clin Biochem. 2008; 41:1055-1058.
11. Kolouchova G, Brcakova E, Hirsova P, etal. Modification of hepatic iron metabolism induced by pravastatin during obstructive cholestasis in rats. Life Sci. 2011; 89:717-724.
12. Ha CE, Ha JS, Theriault AG, Bhagavan NV. Effects of statins on the secretion of human serum albumin in cultured HepG2 cells. J Biomed Sci. 2009; 10:16-32.
13. Hamada Y, Kono TN, Moriguchi Y, etal. Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: A possible mechanism of iron deficiency in chronic kidney disease patients on treatment. Nephrol Dial Transplant. 2008; 23:1886-1891.
14. Lia M, Yin Q, Dang X, Chang J, Zuo R, Zheng Q. Effect of different iron loads on serum and tissue biochemical parameters and liver hepcidin mRNA abundance of neonatal piglets. Arch Anim Nutr. 2011; 65:477-485.
15. Kulaksiz H, Gehrke SG, Janetzko A, etal. Pro-hepcidin: Expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut. 2004; 53:735-743.
16. Aden DP, Fogel A, Plotkin S, etal. Controlled synthesis of HbsAg in a differentiated human liver carcinoma-derived cell line. Nature. 1979; 282:615-616.
17. Acs G, Acs P, Beckwith SM, etal. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001; 61:3561-3565.
18. Benöhr P, Harsch S, Proksch B, Gleiter CH. Does angiotensin II modulate erythropoietin production in HepG2 cells? Nephron Exp Nephrol. 2004; 98:e124-e131.
19. Tavintharan S, Ong CN, Jeyaseelan K, Sivakumar M, Lim SC, Sum CF. Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: A possible role in statin-induced hepatotoxicity? Toxicol Appl Pharmacol. 2007; 223:173-179.
20. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999; 33:63-72.
21. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance haemodialysis patients. Am J Kidney Dis. 2003; 42:761-773.
22. Sirken G, Kung SC, Raja R. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J. 2003; 49:422-425.
23. Swinkels DW, Wetzels JFM. Hepcidin: A new tool in the management of anaemia in patients with chronic kidney disease? Nephrol Dial Transplant. 2008; 23:2450-2453.
24. Ashby DR, Gale DP, Busbridge M, etal. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009; 75:976-981.
25. Kemna EH, Kartikasari AE, van Tits LH, Pickkers P, Tjalsma H, Swinkels DW. Regulation of hepcidin: Insights from biochemical analysis on human serum samples. Blood Cells Mol Dis. 2007; 40:339-346.
26. Verga Falzacappa MV, Casanovas G, Hentze MW, Muckenthaler MU. A bone morphogenetic protein (BMP)-responsive element in the hepcidin promoter controls HFE2-mediated hepatic hepcidin expression and its response to IL-6 in cultured cells. J Mol Med (Berl). 2008; 10:313-317.
27. Burke JP, Watson RW, Murphy M, Docherty NG, Coffey JC, O'Connell PR. Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor β1-mediated activation of intestinal fibroblasts. Br J Surg. 2009; 96:541-551.
28. Yasuhiro H, Masafumi F. Is hepcidin the star player in iron metabolism in chronic kidney disease? Kidney Int. 2009; 75:873-874.
29. Hamadmad SN, Hohl RJ. Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation. Biochem Pharmacol. 2007; 74:590-600.
30. Hamadmad SN, Henry MK, Hohl RJ. Erythropoietin receptor signal transduction requires geranylgeranylation. J Pharmacol Exp Ther. 2005; 316:403-409.
31. Ha CE, Ha JS, Theriault AG, Bhagavan NV. Effects of statins on the secretion of human serum albumin in cultured HepG2 cells. J Biomed Sci. 2009; 16:32-41.